MiMedx Group Inc
Change company Symbol lookup
Select an option...
MDXG MiMedx Group Inc
CATY Cathay General Bancorp
EADSF Airbus SE
ARAY Accuray Inc
TGI Triumph Group Inc
TSNP Tesoro Enterprises Inc
BLV Vanguard Long-Term Bond Index Fund ETF Shares
BP BP PLC
$RFTREES Refinitiv Eurozone ESG Select Index
DIV Global X SuperDividend™ U.S. ETF
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

MiMedx Group, Inc. is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company's Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. Its biomaterial platform technologies include AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. OrthoFlo is amniotic fluid-derived allograft for homologous use. Physio is a bone grafting material consists of bone tissue with no added carrier. CollaFix, its new brand, is its collagen fiber technology designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.

Closing Price
$6.40
Day's Change
0.05 (0.79%)
Bid
--
Ask
--
B/A Size
--
Day's High
6.64
Day's Low
6.35
Volume
(Light)
Volume:
43,698

10-day average volume:
73,332
43,698

(VSLR) Alert: Johnson Fistel Investigates Proposed Sale of Vivint Solar; Are Shareholders Getting a Fair Deal?

9:14 am ET July 7, 2020 (Globe Newswire) Print

Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Vivint Solar, Inc. ("Vivint" or the "Company") (NYSE: VSLR) breached their fiduciary duties in connection with the proposed sale of the Company to Sunrun Inc. (NASDAQ: RUN).

On July 7, 2020, Vivint announced that it had entered into a definitive merger agreement with Sunrun. In an all-stock transaction, each share of Vivint Solar common stock will be exchanged for 0.55 shares of Sunrun common stock, representing a combined Enterprise Value of $9.2 billion based on the closing price of Sunrun's shares on July 6, 2020. However, shareholders will be subject to the future price fluctuation of Sunrun's stock price. Sunrun's shareholders will hold about 64% of the combined company, with the rest owned by Vivint Solar's stockholders.

The investigation concerns whether the Vivint board failed to satisfy its duties to the Company shareholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for Vivint shares of common stock.

If you are a shareholder of Vivint and believe the proposed buyout price is too low or you're interested in learning more about the investigation, please contact lead analyst Jim Baker (jimb@johnsonfistel.com) at 619-814-4471. If emailing, please include a phone number.

Additionally, you can [Click here to join this action]. There is no cost or obligation to you.

About Johnson Fistel, LLP:

Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York, and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit https://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:

Johnson Fistel, LLP

Jim Baker, 619-814-4471

jimb@johnsonfistel.com

[Click here to join this action]

__GNW8366DE3E__IMG

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.